Abstract: Multidrug resistance (MDR) is becoming a significant obstacle for chemotherapeutic treatment in the battle against malignant cancers. Because of the emergence of MDR, higher doses of chemotherapeutic drugs are needed which eventually leads to intolerable toxicity and the death of patients. Different from the normal drug resistance that only resists to the previously administrated drugs, multidrug resistance diminishes the efficacies of a wide range of chemotherapeutic drugs, causing the decrease of intracellular drug concentration and the failure of killing enough cancer cells. Co-administration of multiple chemotherapeutic drugs cannot overcome MDR due to the different pharmacokinetic properties of combined drugs and only brings limited clinical advantage for the patients. Recent progress in nanomedicine and nanotechnology has enabled biomedical scientists to deliver multiple drugs of similar or different acting mechanisms into cancer cells with a predefined releasing profile. Thus, combining nanotechnology and co-delivery technique has the great potential to selectively deliver multiple drugs to overcome MDR and benefit cancer patients.
Introduction
Chemotherapy still plays a vital role in the treatment of different types of cancer. However, the effectiveness of chemotherapy is severely hindered by the emergence of multidrug resistance (MDR), which causes over 90% chemotherapeutic failures of cancer treatments (1) . Although several different cellular mutations can provoke MDR, two of them are under extensive research interests, namely increase of cell surface mediated drug efflux pumps and the up-regulation of anti-apoptotic pathways (2) . In the first scenario, MDR comes from intrinsic high expression of ATP-binding cassette (ABC) transporter proteins including P-glycoprotein (P-gp), multidrug resistance proteins (MRP) and breast cancer resistance protein (BCRP). For example, P-gp can be found overexpressed in lots of MDR cancer cells such as liver, pancreatic and ovarian cells (3) . They can bind with a variety of structurally different chemical compounds and pump them out of the cytoplasm of cancer cells, decreasing the cellular concentration of active drugs and finally leading to low therapeutic outcome (4) (5) (6) (7) (8) . For example, human KB adenocarcinoma cells line KB-CP20 whose multidrug resistance was acquired by treatment with cisplatin and the associated overexpression of MDR1 gene, can also be resistant to many other ly targeting and accumulating in the tumor cells due to the more leaky nature of tumor vasculature (32) (33) (34) (35) . Therefore, combination of nano drug delivery systems and co-delivery of multiple anticancer drugs holds the great potential to surmount the MDR of cancer cells (32) . In this review, we will discuss the recent progress of using nanoparticle to co-deliver multiple pharmaceutical agents to battle against MDR. The delivery of single and multiple traditional chemotherapeutic drugs by nanoparticle with increased anti-MDR effects will be reviewed first. The combination of chemotherapeutic drugs with MDR modulator, sensitive agents as well as therapeutic nucleotides such as regulating siRNA in nanoparticles will also be covered.
With the help of EPR effect of nanoparticles, sufficiently high intracellular level of cytotoxic chemicals can be achieved while using an optimized nanoparticle as delivery system, which may help overcome the MDR of cancer cells (10, 11, 36, 37) . Wang et al managed to deliver doxorubicin (DOX) with disulfide-bridged diblock copolymer PCL-SS-PEEP (38) . Because of the poly(ethyl ethylene phosphate) (PEEP) constructed shell, the synthesized nanoparticle has high affinity to cancer cells and is more efficiently internalized by tumor cells, assisting the escape of active drugs from the pump-off by P-gp and leading to high levels of cellular drug accumulation (Fig.1) . As a result, DOX encapsulated PCL-SS-PEEP nanoparticle shows a rapid release of the free DOX in MDR cancer cells. On the other hand, MDR in cancer cells is often associated with an elevation in the concentration of reductive glutathione (GSH), which makes the disulfide linkage vulnerable and can selectively break disulfide linkage within the PCL-SS-PEEP system in MDR cells, releasing the active DOX inside tumor cells. In vitro study shows the IC 50 value of DOX-loaded PCL-SS-PEEP was only 32% of DOX-loaded PCL-b-PEEP nanoparticles (without disulfide), proving the enhanced selectivity of disulfide-based nanoparticle. In the meantime, a significant decrease of the IC 50 value of DOX-loaded PCL-SS-PEEP in multi-drug resistant MCF-7/ADR cell lines was also observed (~2µg/ml) as compared with free DOX treatment (~20ug/ml).
Besides the inherent EPR effect, nanoparticles decorated with selective ligands such as folate or targeting pep- tides can further enhance the selectivity and the absorption of active therapeutic agents into tumor cells, leading to the increase of the cellular concentration of active drugs (39) (40) (41) . Demonstrated by Wang et al (42) , a multifunctional poly(lactic-co-glycolic acid) (PLGA) and polyethylene glycol (PEG) nanoparticle with folate and cell penetrating peptide (CPP) was prepared for delivering vincristine sulfate (VCR) to tumor and overcoming MDR (Fig.1) . A unique feature here is the dual decoration of nanoparticles with targeting ligand folate and cell penetrating peptide R7 for the increase of accumulation of VCR. The overexpression of folate receptors on human breast carcinoma cells together with strong intracellular penetration effect from arginine-rich CPP R7 allow the synthesized nanoparticles to accumulate VCR in resistant tumor cells by escaping P-glycoprotein mediated drug efflux. In vitro studies shows that VCR-Fol/R7 nanoparticles exhibited much higher cytoxicity (IC 50 : 27.1 ± 1.47 μg/mL) than that of free VCR (IC 50 : 479.80 ± 8.62 μg/mL) in MDR MCF-7/ ADR cells. In vivo study also suggests the strongest antitumor efficacy of the dual decorated nanoparticles while evaluated in nude mice bearing MCF-7/ADR tumors compared with either single VCR or mono-decorated nanoparticle, indicating the promising future of VCR-Fol/R7 nanoparticles to overcome multidrug resistance and improve therapeutic efficacy.
Co-delivery of dual chemotherapeutic drugs
Co-delivery of anticancer drugs with similar or different mechanisms of action has been found to be a promising strategy to overcome undesirable toxicity and other side effects as well as to improve therapeutic index (43) (44) (45) . Chen et al successfully constructed a surfactant nanoparticle with Pluronic P105-DOX conjugate containing a hydrophobic core (46) , which can be used to entrap another chemotherapeutic drug paclitaxel (PTX). DOX is generally considered a hydrophilic anticancer drug binding with DNA by intercalation while PTX is highly hydrophobic and inhibits microtubules disassembly to induce apoptosis. Patients with metastatic breast cancers benefits from the co-administration of DOX and PTX. Therefore, the dual drug loaded micelles (PF-DOX-PTX) offer great advantages in terms of achieving synergistic effect of these two drug substances. Study results showed that a sustained release profile can be achieved for both DOX and PTX in vitro with effectively accumulation of both drugs in MDR cancer cells MCF-7/ADR. Both DOX and PTX release rates are increased in pH = 5.0 buffer which mimics the acidic microenvironment of lysosome compared with normal pH = 7.4 PBS buffer. Furthermore, in vitro cytotoxicity, cell apoptosis and cell cycle arrest studies indicated that PF-DOX-PTX had better antitumor efficacy in MDR cancer cells compared to those of singledrug loaded micelles. More importantly, a much stronger antitumor efficacy in MCF-7/ADR tumor-bearing mice was observed in PF-DOX-PTX group than that of combined administration of free DOX and PTX. For example, PF-DOX-PTX shows IC 50 values as 0.0017 and 0.328 μg/ mL while co-administration of DOX and PTX only has IC 50 of 0.014 and 15.011 μg/mL in MCF-7 and MCF-7/ ADR cell lines respectively. This example proves the superior efficiency of co-delivery chemotherapeutics with nanoparticles over the conventional co-administration.
Chloroquine (CQ) can be selectively accumulated in lysosomes and execute its anti-tumor function through inhibition of autophagy. Therefore, combining CQ with certain anticancer drugs is a good choice to inhibit autophagy-dependent resistance for chemotherapy and enhance the anticancer effects. Shi et al co-delivered anticancer drug docetaxel (DTX) and CQ in a complex micelle composed of PEO-PPO-PCL (poly(ethylene oxide)-poly(propylene oxide)-poly(ε-caprolactone)) and TPGS (D-α-tocopheryl poly(ethyleneglycol)) for enhancing anticancer effects (47) The co-administration of paclitaxel (PTX) and 5-fluoroucacil (5-FU) has been tested to show promising efficiency in MDR cancer therapy such as on gastric or breast cancer patients. However, it is very challenging to control the molar ratio of the two drugs and tune the different pharmacokinetic and bioavailability properties with simple co-administration. To address this problem, a corematched nanoemulsions (NE) functionalized by vitamin E (VE) and tocopherol poly(ethylene glycol)succinate (TPGS) was developed by Ma et al to co-deliver hydrophobic and hydrophilic drugs (PTX and 5-FU) at the same time in order to achieve synergistic effects and overcome PTX resistance in a MDR human epidermal carcinoma cell line (48) 
The dual-drug loaded NE exhibited concentration and time-dependent cytotoxicity against PTX-sensitive KB-3-1 cells and PTX-resistant KB-8-5 cells (Fig.2) . Interestingly, the IC 50 of PTX-VE-5-FU-TPGS nanoemulsion was 0.54 μM in KB-8-5 cells and 1.38 μM in KB-3-1 cells, showing a resistant index 0.39. While without the co-delivery strategy, the resistant index of PTX increases to 2.96, showing that the synergism of PTX and 5-FU could reverse MDR through co-delivery in a single nanoparticle for cancer therapy.
Co-delivery of Chemotherapeutics with MDR Inhibitor
Therapeutic nanoparticles containing the combination of cytotoxic drugs and efflux pump (e.g, P-gp) inhibitors, such as cyclosporine, verapamil and tariquidar, hold the potential to suppress MDR effect while still maintaining effective cytotoxicity (49) . Such co-delivery strategy can also address the poor pharmacokinetic properties and high systemic toxicities often associated with MDR inhibitors. Zhu et al used the poly (lactic-co-glycolic acid) (PLGA) nanoparticle for co-delivery of docetaxel(DTX) with tocopherol poly(ethylene glycol)succinate (TPGS) (50) . The co-delivered TPGS can serve as an active matrix component to inhibit P-gp ATPase and drug efflux for overcoming MDR. Four different DTX-loaded PLGA NPs with 0, 10, 20 and 40% of TPGS were prepared and found of size ranged 100 to 120 nm and encapsulation efficiency between 85 to 95% at drug loading level around 10%. The IC 50 values of the free DTX and the aforementioned NPs of 0, 10, 20% TPGS were 2.619 and 0.474, 0.040, 0.009 µg/mL respectively after incubated in HeLa cells for 48 hours, showing great improvement in cell cytotoxicity. The increase of cell cytotoxicity can be attributed to the inhibition of P-gp ATPase from TPGS, resulting in higher cellular concentration of DTX and better therapeutic efficacy both in vitro and in vivo.
Tariquidar is another potent and specific P-gp inhibitor and can sensitize the resistant cell lines with great promise to reverse the MDR caused by the P-gp overexpression. One of the biggest concerns for the combination use of tariquidar and chemotherapeutics is the non-specific binding of tariquidar to the P-gp in normal tissues such as blood brain barrier and gastrointestinal track. Obviously, higher selectivity provided by nanoparticle co-delivery system can help address the non-specificity issue. Patel et al co-delivered tariquidar and paclitaxel (PTX) with long-circulating liposomes to reverse the MDR (51). The liposome is composed of L-α-phosphatidylcholine (EPC), 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), cholesterol (CHOL) and polyethylene glycol 2000-phosphatidylethanolamine (PEG 2K PE). Tariquidar and paclitaxel-loaded co-delivery liposomes showed significant resensitization of chemo drugs to the resistant cancer cells. For example, the IC 50 values for PTX were 27.11 nM and 2743 nM in SKOV-3 and MDR SKOV-3TR cells when treated with paclitaxel alone. The value can dramatically decrease to 17.68 nM and 34 nM respectively when treated with synthesized dual-drug delivered liposomes, demonstrating the reversal of the MDR by the co-delivering tariquidar with active cytotoxic drugs.
Verapamil (Vera) is a non-dihydropyridine calcium channel blocker, normally used for the treatment of hypertension, angina pectoris and cardiac arrhythmia. It was also discovered that Vera can block the pathway of a drug efflux pump such as P-gp, making it a great candidate for co-delivery strategy (52, 53) . Qin et al engineered a hydrogel nanoparticle composed of co-polymerized acrylamide (AAm), 2-carboxyethyl acrylate (CEA) and 3-(acryloyloxy)-2-hydroxypropyl methacrylate (AHM) (54). The resulting nanoparticle was then to serve as a carrier to co-deliver DOX and Vera, aiming at alleviating tumor MDR. One unique feature here is either Vera or Dox is post-loaded into nanoparticles, which gives more freedom to adjust the relative ratios of Vera and DOX. DOX resistant NCI/ADR-RES cells were used to study the in vitro cytotoxicity of the synthesized drug-loaded nanoparticles. While the IC 50 values of DOX and DOX only nanoparticles were >20 and 19 µM, co-delivery of DOX nanoparticle with Vera gives IC 50 value of 4.5 µM compared with that of 10 µM when co-administrated with DOX and Vera. More importantly, co-delivery of DOX nanoparticle and Vera nanoparticle shows the strongest antitumor efficiency with IC 50 of only 2.5 µM, suggesting a promising route for overcoming MDR.
Co-delivery of Chemotherapeutics with Sensitizer
In response to MDR caused by the alterations of the apoptosis pathways, sensitizer compounds that can repair the dysfunctional apoptotic signaling are being delivered with chemotherapeutic drugs within nanoparticles. One example was demonstrated by Fan et al to use folate-chitosan (FA-CS) nanoparticle for the co-delivery of pyrrolidinedithiocarbamate (PDTC) and doxorubicin (DOX) (55) . PDTC is a NF-κB inhibitor and often used as a sensitizer of the anticancer drug. NF-κB is widely used as a regulator of genes to control cell proliferation and cell survival. Therefore, resensitizing NF-κB pathway could enhance the sensitivity of tumor cells to apoptosis and help reduce the related MDR. Compared with pure DOX and micelle without either FA or PDTC, the FA-CS nanoparticle with both DOX and PDTC shows lowest IC 50 in multidrug resistant HepG-2 liver cancer cells as 0.028 mg/L. Without co-delivery with PDTC, the IC 50 value in the same cell lines increases to 0.059 mg/L, showing that co-delivery with sensitizer can restore and even enhance the cytotoxicity of delivered chemotherapeutics. Through folate mediation, FA-CS/DOX-PDTC nanoparticle also has more cellular uptake of DOX than pure DOX and FA-CS/DOX micelle in HepG-2 cells.
Curcumin (CUR) is a polyphenol with several biological functions such as anticancer activity. CUR can also act as a mediator to down-regulate both PI3K/AKT and NF-κB pathways. PI3K/AKT pathway is found to be overactive in many MDR cancer cells, allowing reduced apoptosis and increased proliferation. Co-delivery with curcumin is then promising for chemotherapeutic drugs to escapes from MDR. Wang et al designed polymeric micelles with TPGS2000 (Di-tocopherol polyethylene glycol 2000 succinate) and PEG2000-DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy-(polyethylene glycol)-2000) to co-deliver DOX and CUR with high encapsulation efficiency and stability (56) . Co-delivery with CUR increases the cellular uptake and improves anticancer efficacy of DOX in multidrug resistant MCF7/ ADR cells. Meanwhile, co-delivery of DOX and CUR in nanoparticle micelle significantly enhances cellular apoptosis in vitro, which induced 74.9% of MCF7/ADR cell apoptosis compared with only 4.1% for DOX-only treatment. Remarkable loss of tumor weight was also observed in vivo, suggesting the synergistic effects of co-delivery of DOX and CUR. Similarly, Misra et al investigated the co-delivery of DOX and CUR into chronic myeloid leukemia K562 cells with poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles (57) . With the co-delivery of CUR, the expression of MDR1 and BCL-2 at the mRNA level in K562 cells were dramatically decreased from 43.4 to 3.5 fold and 6.50 to 1.07 fold respectively. Attractively, DOX-CUR nanoparticle also shows strongest in vitro cytotoxicity in chronic myeloid leukemia K562 cells compared with DOX-CUR solution. The IC 50 value of DOX-CUR nanoparticle was 0.1±0.93 µg/ml while that of DOX-CUR solution was 6.7±0.91 µg/ml. Both of these two examples demonstrate that the co-delivery of DOX with CUR has significant synergistic effects to bring success against MDR in cancer therapy.
Lipid C6 ceramide serves as a key messenger in programmed cell death and can be used to decrease the apoptosis threshold in tumor cells. Wang et al developed a nanoparticle micelle formulation to deliver DOX with ceramide into multidrug resistant leukemia cells P388/ ADR (58) . The lipid nano micelle was composed of 1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine (PazPC), DOX, ceramide and PEG-2000. The study shows DOX-ceramide micelle has IC 50 value of 226.78 nM against MDR P388/ADR cells compared with 523.38 nM from the no-ceramide DOX micelle, showing the effectiveness of delivering ceramide to increase the efficacy of DOX against drug resistant leukemia cells.
Co-delivery of Chemotherapeutics with siRNA
The advancement of gene engineering especially the progress in small interfering RNA(siRNA) technology has provided cancer treatment with promise highly specific therapeutic weapons (59, 60) . siRNA works through interfering with the expression of specific genes with complementary nucleotide sequences, resulting in no translation (2). While direct of injection of the RNA molecules is not effective due to the rapid degradation of the molecule in serum, nanoparticles can serve to entrap the siRNA as cargo and protect them from the outside environment, leading to the potential success of overcoming MDR (61, 62) . Thus, co-delivery of MDR-targeted siRNA such as targeting MRP1 or BCL2 with cytotoxic drugs is attracting more and more interests from biomedical scientists.
Taratula et al developed a multifunctional nanostructured lipid carrier (NPL) to co-deliver anticancer drugs and multiple siRNA (BCL2 and MRP1) to enhance antitumor activity and suppress multidrug resistance (63) . A key feature here is that the synthesized nanoparticle contains dual siRNA silencing both BCL2 and MRP1 besides the encapsulated chemotherapeutic drugs (doxorubicin or paclitaxel). Meanwhile the surface is also decorated with a modified synthetic analog of luteinizing hormone-releasing hormone (LHRH) as a targeting agent towards lung cancer cells. In vitro test shows nanoparticle with both PTX, siR-NA and LHRH has best anticancer effects with IC 50 value less than 1 µg/ml while the nanoparticle with only PTX and LHRH shows IC 50 value around 10 µg/ml human lung cancer cells A549. RT-PCR reveals that both of the loaded siRNA (targeted to MRP1 and BCL2 mRNAs) successfully suppressed targeted mRNA isolated from A549 human lung cancer cells after being released from the delivery nanoparticle. In vivo study of lung tumor models shows the fully equipped LHRH-NLC-TAX-siRNAs (MRP1 and BCL2) can shrink the tumor size from 45 mm 3 to 2.6 ± 3.0 mm 3 while the one without targeting siRNA can only make it to 20.8 ± 4.4 mm 3 after 4 weeks treatment. Dendrimers are repetitively branched molecules with highly symmetric spherical shape. Cationic dendrimers have positively charged surface and are often used to bind and delivery negatively charged biomolecules through the electrostatic interaction. Biswas et al used poly(ethylene glycol)-dioleoylphosphatidyl ethanolamine (PEG-DOPE) to construct nanoparticle micelles for effective delivery of hydrophobic anticancer drugs (64) . At the meanwhile, a G(4)-Polyamidoamine (PAMAM) cationic dendrimer was synthesized as a cationic carrier of MDR targeting siRNA and conjugated with PEG-DOPE micelle (G(4)-D-PEG-DOPE), which can form nanoparticle with diameter around 60.4 nm. Two micelle systems, G(4)-D-PEG-DOPE (MD) and G(4)-D-PEG-DOPE/PEG-DOPE(1:1, MDM), were both evaluated for drug delivery efficiency and cytotoxicity. After self-assembly, the resulting nano micelles can be used to co-deliver the binded siRNA and the encapsulated anticancer drug (DOX). GFP-specific siRNA was used as a model nucleotide and in vitro gene silencing shows the silencing efficacy of both MD and MDM were significantly higher (22%, 18% respectively) in the siRNA-PEG-DOPE-Dendrimer complex compared with G(4)-D (10%) only, showing the great potential of using this technique to circumvent the problem of MDR.
Conclusion
Combination of nano drug delivery systems and co-delivery of multiple drugs holds the great potential to surmount MDR in the treatment of cancers. Different strategies based on different combination of drugs can be realized by carefully selection of nano delivery system. While co-delivery of multiple chemotherapeutic drugs with similar or different mechanisms can be beneficial to overcome MDR, future development of co-delivery with nanoparticle is expected to be focused on resensitizing resistant cancer cells by either MDR inhibitor or through the modulation of siRNA. Furthermore, the development of combinational use of siRNA with chemotherapeutic drugs can help advance the treatment with precision medicine, allowing biomedical scientist and oncologists to achieve the ideal combination therapy effects.
